reports
Axogen, Inc. to report 2025 first quarter financial results on May 8, ...
Axogen, Inc. to report 2025 first quarter financial results on May 8, 2025 ALACHUA and TAMPA, Fla., April 24, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it will report 2025 first quarter financial results on Thursday, May 8, 2025, before the market opens. Axogen management will host an investment-community conference call and webcast at 8 a.m. ET following the release. Investors interested in participating in the conference call by phone may do so by di...
Lifecore Biomedical to Participate at Upcoming CDMO Live 2025 Conferen...
Lifecore Biomedical to Participate at Upcoming CDMO Live 2025 Conference CHASKA, Minn., April 22, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: ) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that the company will participate in the upcoming CDMO Live 2025 conference. Billed as a premiere partnering event for the biopharma outsourcing industry, CDMO Live will take place May 7-8, 2025, in Rotterdam, Netherlands. During the conference, Jackie Klecker, Lifecore’s executive vice president, quality and development ...
Lifecore Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)...
Lifecore Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CHASKA, Minn., April 16, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”) a fully integrated contract development and manufacturing organization (“CDMO”), today announced that Lifecore granted a restricted stock unit (“RSU”) award with respect to 45,000 shares of its common stock, an option for 210,000 shares of stock, an RSU for 170,000 shares of common stock, and a performance stock unit (“PSU”) award for up to 370,000 shares of its common stock to Thomas D. Salus, Lifecore’s newly hi...
Lifecore Biomedical Appoints Thomas D. Salus as Chief Legal and Admini...
Lifecore Biomedical Appoints Thomas D. Salus as Chief Legal and Administration Officer Mr. Salus Brings More than 30 Years of Broad-Based Legal and Management Expertise Highlighted by Extensive Experience within Life Sciences Industry Significantly Elevates Lifecore’s Capabilities Across Corporate Governance, Transactional Activities, and SEC Reporting and Compliance CHASKA, Minn., April 14, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: ) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that it has appointed Th...
Eyenovia Provides Development Update on Optejet User Filled Device (UF...
Eyenovia Provides Development Update on Optejet User Filled Device (UFD) On track for regulatory submission seeking marketing approval of the Optejet UFD in Q4 2025 NEW YORK, April 10, 2025 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) (“Eyenovia” or the “Company”), an ophthalmic technology company developing and commercializing advanced products leveraging its proprietary Optejet topical ophthalmic medication dispensing platform, today provided an update on recent progress made in the development of the Company’s novel Optejet UFD. The user-filled Optejet is designed to work with a...
Lifecore Biomedical Reports Third Quarter Fiscal 2025 Financial Result...
Lifecore Biomedical Reports Third Quarter Fiscal 2025 Financial Results and Provides Corporate Update -- Recorded Revenues of $35.2 Million for Q3 Fiscal 2025 -- -- Signed Multiple Development Agreements with New and Existing Customers -- -- Strengthened Balance Sheet through Sale of Excess Capital Equipment, Raising Approximately $17.0 Million -- Conference Call Today at 4:30pm ET CHASKA, Minn., April 03, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announ...
- Dave Nicoski
- Ross LaDuke
Vital Signs: Actionable charts
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
LOPE GRAND CANYON EDUCATION INC.
LNDC LANDEC CORP.
HOO HERBALIFE NUTRITION LTD.
DLTR DOLLAR TREE INC.
DG DOLLAR GENERAL CORPORATION
CAAS CHINA AUTOMOTIVE SYSTEMS ADS (N SHARES)
BFAM BRIGHT HORIZONS FAMILY SOLUTIONS INC.
AZO AUTOZONE INC.
ADMA ADMA BIOLOGICS INC
ACU ACME UNITED CORP.
OSTK OVERSTOCK.COM INC.
UVV UNIVERSAL CORP
FDP FRESH DEL MONTE PRODUCE INC.
TATT TAT TECHNOLOGIES LTD.
WMK WEIS MARKETS INC.
KINS KINGSTONE COS. INC.
NC NACCO INDUSTRIES INC. CL A
CHCI COMSTOCK HOLDING COMPANIES
VLGEA VILLAGE SUPER MARKET INC. CL A
LAUR LAUREATE EDUCATION INC. CLASS A
CMCL CALEDONIA MINING CORPORATION
ABT ABBOTT LABORATORIES
BRP BRP GROUP
GRPN GROUPON INC.
CNXC CONCENTRIX
DRVN DRIVEN BRANDS HOLDINGS
ALHC ALIGNMENT HEALTHCARE INC
ADSE ADS TEC ENERGY PLC
KLG_w WK KELLOGG CO
TRVG TRIVAGO N.V.
BG BUNGE LIMITED
IDR IDAHO STRATEGIC RESOURCES INC
DBD DIEBOLD NIXDORF INCORPORATED
CCB CHASE CAPITAL VIII CAP SEC H 8.25%
MNPR MONOPAR THERAPEUTICS INC.
AEVA AEVA TECHNOLOGIES INC.
ORLY OREILLY AUTOMOTIVE INC CDA
Lifecore Biomedical to Report Financial Results for Third Quarter of F...
Lifecore Biomedical to Report Financial Results for Third Quarter of Fiscal 2025 on April 3, 2025 Webcast Scheduled for Thursday, April 3 at 4:30 p.m. Eastern CHASKA, Minn., March 27, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: ) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that it will report financial results for the third quarter of fiscal year 2025 on Thursday, April 3, 2025, after market close. At 4:30 p.m. Eastern Time that day, members of Lifecore’s senior management team will host a webcast to disc...
Axogen Announces Appointment of Rick Ditto as Vice President, Global H...
Axogen Announces Appointment of Rick Ditto as Vice President, Global Health Economics, Reimbursement & Policy, and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) ALACHUA, Fla. and TAMPA, Fla., March 24, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced the appointment of Rick Ditto as Vice President, Global Health Economics, Reimbursement & Policy. Mr. Ditto will report to Michael Dale, President, and Chief Executive Officer, and will lead the development of...
Eyenovia Enters into Non-Binding Letter of Intent to Effect Reverse Me...
Eyenovia Enters into Non-Binding Letter of Intent to Effect Reverse Merger with Betaliq Combination, if successful, would create a new publicly-listed eye care company combining Betaliq’s EyeSol® water-free drug delivery technology for glaucoma with Eyenovia’s Optejet® device platform The combined company would continue marketing Eyenovia’s FDA-approved products – and plans to in-license additional products to generate near-term revenue NEW YORK, March 20, 2025 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) (“Eyenovia” or the “Company”), an ophthalmic technology company developing an...
Humanetics Selects Lifecore Biomedical to Deliver CDMO Services Suppor...
Humanetics Selects Lifecore Biomedical to Deliver CDMO Services Supporting Development of BIO 300 for the Prevention of Acute Radiation Syndrome Humanetics’ Novel Radioprotective Agent Being Developed with Funding from Department of Defense as Radiation Medical Countermeasure (MCM) Lifecore to Carry Out Tech Transfer and Analytical Method Activities, including Filling of Pilot Batch CHASKA, Minn. and MINNEAPOLIS, March 17, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: ) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), and Human...
Lifecore Biomedical to Participate in Upcoming Investor and Industry C...
Lifecore Biomedical to Participate in Upcoming Investor and Industry Conferences CHASKA, Minn., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: ) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that the company will participate in multiple upcoming investor conferences and industry events. Details regarding Lifecore’s participation are as follows: TD Cowen 45th Annual Health Care ConferenceDetails: Paul Josephs, chief executive officer, will deliver a corporate presentation and Lifecore management will ...
Eyenovia Regains Compliance with All Nasdaq Continued Listing Requirem...
Eyenovia Regains Compliance with All Nasdaq Continued Listing Requirements NEW YORK, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) (“Eyenovia” or the “Company"), an ophthalmic technology company focused on completing development of its proprietary Optejet® device, today announced that it has been informed by staff of The Nasdaq Stock Market LLC that the Company has regained compliance with all Nasdaq Capital Market continued listing requirements, including Nasdaq Listing Rule 5550(a)(2), the minimum bid price requirement rule, and Listing Rule 5810(c)(3)(A)(iii), the low...
Axogen, Inc. To Host Analyst & Investor Day on March 4th
Axogen, Inc. To Host Analyst & Investor Day on March 4th ALACHUA, Fla. and TAMPA, Fla., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, will hold its Analyst & Investor Day on March 4, 2025, between 9am-12pm Eastern. Featured speakers will include Chief Executive Officer - Michael Dale, Chief Financial Officer - Nir Naor, and other senior members of the leadership team. During the event, the Axogen team will offer an overview of the business, strategic initiatives and g...
Axogen, Inc. Reports 2024 Fourth Quarter and Full-Year Financial Resul...
Axogen, Inc. Reports 2024 Fourth Quarter and Full-Year Financial Results ALACHUA, Fla. and TAMPA, Fla., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights for the fourth quarter and full-year ended December 31, 2024. Fourth Quarter 2024 Financial Results and Business Highlights Fourth quarter revenue was $49.4 million, a 15.1% increase compared to the fourth quarter of 2023.Gross margin was 76.1% for the fourth ...
Eyenovia, Inc. Announces Debt Restructuring Including Amendment to Sen...
Eyenovia, Inc. Announces Debt Restructuring Including Amendment to Senior Secured Debt, Improving Cash Runway to Allow for the Evaluation of Strategic Alternatives Amendment provides financial flexibility to the Company by deferring all interest as well as principal redemption payments through September 2025, while reducing near-term cash needs NEW YORK, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) (“Eyenovia” or the “Company”), an ophthalmic technology company focused on completing development of its proprietary Optejet® device, today announced that it has entered in...
Axogen, Inc. to report 2024 fourth quarter and full year financial res...
Axogen, Inc. to report 2024 fourth quarter and full year financial results on February 25, 2025 ALACHUA, Fla. and TAMPA, Fla., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it will report 2024 fourth quarter and full year financial results on Tuesday, February 25, 2025, before the market opens. Axogen management will host an investment-community conference call and webcast at 8 a.m. ET following the release. Investors interested in participating i...
- Jonathan Moreland
XNCR XENCOR INC.
RLI RLI CORP.
PBF PBF ENERGY INC. CLASS A
ORRF ORRSTOWN FINANCIAL SERVICES INC.
NEOG NEOGEN CORPORATION
MKL MARKEL CORPORATION
LAKE LAKELAND INDUSTRIES INC.
JBLU JETBLUE AIRWAYS CORPORATION
EL ESTEE LAUDER COMPANIES INC. CLASS A
CTSO CYTOSORBENTS
BUSE FIRST BUSEY CORPORATION
BAH BOOZ ALLEN HAMILTON HOLDING CORPORATION CLASS A
CBFV CB FINANCIAL SERVICES INC.
MUR MURPHY OIL CORPORATION
OLN OLIN CORPORATION
WVE WAVE LIFE SCIENCES
OVLY OAK VALLEY BANCORP
FLWS 1-800-FLOWERS.COM CL A
KALV KALVISTA PHARMACEUTICALS
ANAB ANAPTYSBIO INC.
MHI PIONEER MUNICIPAL HIGH INCOME TRUST
MPB MID PENN BANCORP INC.
CIK CREDIT SUISSE ASSET MANAGEMENT INCOME FUND INC.
COGT COGINT
NWFL INC.
FRAF NORWOOD FINANCIAL CORP.
ETST FRANKLIN FINANCIAL SERVICES CO.
LOOP EARTH SCIENCE TECH
ANIX LOOP INDUSTRIES
MFON ANIXA BIOSCIENCES
PNTG MOBIVITY HOLDINGS CORP.
ZYME PENNANT GROUP
PLCE ZYMEWORKS INC.
ALLY THE CHILDREN'S PLACE RETAIL STORES
IMNM INC.
CTOS GMAC LLC
IBRX IMMUNOME
BHRB CUSTOM TRUCK ONE SOURCE
VGAS INC.
TLSI IMMUNITYBIO INC
TKO BURKE & HERBERT BANK & TR/VA
PCSA VERDE CLEAN FUELS INC
PROP TRISALUS LIFE SCIENCES INC
MIO TKO GROUP HOLDINGS
MXF INC.
SUNS PROCESSA PHARMACEUTICALS INC
BATRK PRAIRIE OPERATING CO.
MYCB PIONEER MUN HIGH INCOME OPPORTUNITIES FD INC
THE MEXICO FUND
INC.
SUNRISE REALTY TRUST
LIBERTY MEDIA CORPORATION
MY CITY BUILDERS
INC.
Eyenovia Announces Progress on Next-Generation User-Filled Optejet Dis...
Eyenovia Announces Progress on Next-Generation User-Filled Optejet Dispensing Device Eyenovia plans to submit for U.S. device regulatory approval in Q4 of this year, marking a key step toward commercialization NEW YORK, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) (“Eyenovia” or the “Company”), an ophthalmic technology company focused on completing development of its proprietary Optejet® device, today announces recent progress on the development of its user-filled spray dispenser. “Millions of consumers have difficulty with traditional eye drops, including difficul...
Axogen Announces Appointment of Jesse Bishop as Vice President of Regu...
Axogen Announces Appointment of Jesse Bishop as Vice President of Regulatory Affairs and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) ALACHUA, Fla. and TAMPA, Fla., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced the appointment of Jesse Bishop as Vice President of Regulatory Affairs. Mr. Bishop will report to Michael Dale, President, and Chief Executive Officer, and will lead the development and execution of domestic and international regulator...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.